+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07667335

Study of Enfortumab Vedotin and Pembrolizumab Combined With Quemliclustat for Treating Advanced or Metastatic Urothelial Cancer

Led by Fred Hutchinson Cancer Center · Updated on 2026-10-22

27

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination treatment involving quemliclustat, enfortumab vedotin, and pembrolizumab for patients with unresectable locally advanced or metastatic urothelial cancer affecting the bladder, renal pelvis, or ureter. This phase IbII trial aims to test the safety, side effects, and best dose of the combination and assess how well it works to treat cancer that has spread beyond the primary site. Enfortumab vedotin is a targeted antibody-drug conjugate, pembrolizumab is an immunotherapy to help the immune system attack cancer, and quemliclustat may stop tumor growth by blocking enzymes needed for cell growth.

CONDITIONS

Brief Title

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

Research Team

R

Rosa Nadal Rios, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here